BACKGROUND Sarcopenia is an age-related decline in skeletal muscle mass,which depends on an assessment of muscle strength and muscle mass.The diagnostic definition of sarcopenia varies by region.AIM To determine the o...BACKGROUND Sarcopenia is an age-related decline in skeletal muscle mass,which depends on an assessment of muscle strength and muscle mass.The diagnostic definition of sarcopenia varies by region.AIM To determine the optimal diagnostic criteria for sarcopenia in a plateau population.Cut off values for the components of diagnostic algorithms for sarcopenia in plateau populations should consider altitude.METHODS One hundred and fifty subjects aged>60 years attending a tertiary comprehensive hospital in the city of Xining(elevation:2260 m)between October and December 2018 were enrolled.Handgrip strength,muscle mass,and physical performance were measured.Sarcopenia was diagnosed according to the Asian Working Group for Sarcopenia(AWGS)2019 criteria,Beijing criteria,and Lasha criteria.RESULTS Across diagnostic criteria,there were significant differences in the prevalence of sarcopenia in the overall population and stratified by gender.The prevalence of sarcopenia measured by the AWGS 2019 or Lasha criteria was significantly higher in female compared to male subjects.In males,the prevalence of sarcopenia measured by the Beijing criteria was significantly higher in subjects who identified as Han compared to Minority.In females,there were no significant differences in the prevalence of sarcopenia by ethnicity according to any criteria.CONCLUSION The Lasha criteria provided a lower prevalence of sarcopenia(males,8.7%;females,22.41%;overall,14%)and were able to differentiate between males and females.The Lasha criteria are likely most appropriate for detection of sarcopenia in this plateau population.We recommend the Lasha criteria for detection of sarcopenia in Xining.展开更多
Aim: Sorafenib is a multi-tyrosine kinase inhibitor and the standard therapy for advanced hepatocellular carcinoma (HCC). This retrospective study aimed to observe the anti-fibrotic effect of sorafenib in patients wit...Aim: Sorafenib is a multi-tyrosine kinase inhibitor and the standard therapy for advanced hepatocellular carcinoma (HCC). This retrospective study aimed to observe the anti-fibrotic effect of sorafenib in patients with advanced HCC. Methods: Seventeen patients with advanced HCC were recruited. Shear wave velocity (SWV) using acoustic radiation force impulse elastography and non-invasive serum markers for liver fibrosis, such as the aspartate aminotransferase (AST) to alanine aminotransferase ratio (AAR), the AST to platelet ratio index, the fibrosis-4 index and the Lok index, were recorded at the beginning of sorafenib treatment and 3-6 months after sorafenib treatment in 2014-2015. Results: Nine (52.9%) patients achieved disease control status and 8 had progressive disease after a mean duration of 11.1 months with sorafenib treatment. The mean SWV decreased from 2.37 m/s at the beginning to 1.90 m/s after sorafenib treatment (P < 0.01). This trend was observed in patients with and without liver cirrhosis (from 2.49 to 2.06 m/s, P = 0.06, and from 2.32 to 1.69 m/s, P < 0.05, respectively). Among the non-invasive serum markers, no statistically significant differences were observed except for the AAR in the cirrhotic group. Conclusion: Sorafenib has potential antif-ibrotic effects in patients with advanced HCC.展开更多
基金Supported by the Chinese Academy of Medical Sciences,Peking Union Medical College Hospital,No.2018PT33001.
文摘BACKGROUND Sarcopenia is an age-related decline in skeletal muscle mass,which depends on an assessment of muscle strength and muscle mass.The diagnostic definition of sarcopenia varies by region.AIM To determine the optimal diagnostic criteria for sarcopenia in a plateau population.Cut off values for the components of diagnostic algorithms for sarcopenia in plateau populations should consider altitude.METHODS One hundred and fifty subjects aged>60 years attending a tertiary comprehensive hospital in the city of Xining(elevation:2260 m)between October and December 2018 were enrolled.Handgrip strength,muscle mass,and physical performance were measured.Sarcopenia was diagnosed according to the Asian Working Group for Sarcopenia(AWGS)2019 criteria,Beijing criteria,and Lasha criteria.RESULTS Across diagnostic criteria,there were significant differences in the prevalence of sarcopenia in the overall population and stratified by gender.The prevalence of sarcopenia measured by the AWGS 2019 or Lasha criteria was significantly higher in female compared to male subjects.In males,the prevalence of sarcopenia measured by the Beijing criteria was significantly higher in subjects who identified as Han compared to Minority.In females,there were no significant differences in the prevalence of sarcopenia by ethnicity according to any criteria.CONCLUSION The Lasha criteria provided a lower prevalence of sarcopenia(males,8.7%;females,22.41%;overall,14%)and were able to differentiate between males and females.The Lasha criteria are likely most appropriate for detection of sarcopenia in this plateau population.We recommend the Lasha criteria for detection of sarcopenia in Xining.
文摘Aim: Sorafenib is a multi-tyrosine kinase inhibitor and the standard therapy for advanced hepatocellular carcinoma (HCC). This retrospective study aimed to observe the anti-fibrotic effect of sorafenib in patients with advanced HCC. Methods: Seventeen patients with advanced HCC were recruited. Shear wave velocity (SWV) using acoustic radiation force impulse elastography and non-invasive serum markers for liver fibrosis, such as the aspartate aminotransferase (AST) to alanine aminotransferase ratio (AAR), the AST to platelet ratio index, the fibrosis-4 index and the Lok index, were recorded at the beginning of sorafenib treatment and 3-6 months after sorafenib treatment in 2014-2015. Results: Nine (52.9%) patients achieved disease control status and 8 had progressive disease after a mean duration of 11.1 months with sorafenib treatment. The mean SWV decreased from 2.37 m/s at the beginning to 1.90 m/s after sorafenib treatment (P < 0.01). This trend was observed in patients with and without liver cirrhosis (from 2.49 to 2.06 m/s, P = 0.06, and from 2.32 to 1.69 m/s, P < 0.05, respectively). Among the non-invasive serum markers, no statistically significant differences were observed except for the AAR in the cirrhotic group. Conclusion: Sorafenib has potential antif-ibrotic effects in patients with advanced HCC.
